The combined administration of SGP and PTX could improve intestinal barrier function by suppressing endotoxemia and upregulating tight junction proteins, such as E-cadherin, β-catenin, occludin and ZO-1. The gene discussed is TJP1; the disease is serum lipopolysaccharide activity.